FDA finds link between Revlimid and skin diseases
The FDA’s post-market safety review has uncovered a link between lenalidomide (marketed as the drug Revlimid) and serious skin reactions, including Stevens Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN).